Post-marketing Clinical Study of Irbesartan

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080220722

Enrollment

100

Registered

2009-04-20

Start date

2009-04-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

essential hypertension

Interventions

investigational material(s) Generic name etc : AVAPRO tablet, Irbetan tablet (Irbesartan) INN of investigational material : Therapeutic category code : 214 Antihypertensives Dosage and Administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients whose trough seated blood pressure at the end of washout period >= 160/90 mmHg or >= 150/95 mmHg

Exclusion criteria

Exclusion criteria: Patients with renal, hepatic or heart disease

Design outcomes

Primary

Measure	Time frame
Adverse events and adverse drug reactions, etc.	—

Secondary

Measure	Time frame
Change from baseline in trough seated diastolic blood pressure, etc.	—

Contacts

Public Contact; ;

Dainippon Sumitomo Pharma Co., Ltd.;Shionogi & Co., Ltd.

;;

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026